Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis

 
• By Jessica Merrill
  
gold medal
Takeda thinks its TYK2 inhibitor could be best in class • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immunological

More from Therapy Areas